Search our Database of Scientific Publications and Authors

I’m looking for a

    3348 results match your criteria Prolactinoma

    1 OF 67

    Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
    Eur J Pediatr 2017 Nov 22. Epub 2017 Nov 22.
    Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Rahel-Straus-Strasse 10, 26133, Oldenburg, Germany.
    Prolactinoma is a rare pituitary adenoma secreting prolactin. Studies on diagnostics, treatment, and prognosis in pediatric prolactinoma patients are rare. We analyzed clinical presentation, response to treatment, and prognosis of 27 pediatric prolactinoma patients (10 m/17 f. Read More

    [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists].
    Vnitr Lek 2017 ;63(9):561-565
    Adverse effect of dopamine agonists on the heart valves aroused much attention some time ago. Gradually, as data accumulated, the approach to the problem was rationalised and further examinations were only recommended in indicated cases. The paper reviews the current knowledge about the treatment of hyperprolactinemia with dopamine agonists and the risk of valvular disease. Read More

    Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: A unique description.
    Neuropathology 2017 Nov 6. Epub 2017 Nov 6.
    Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
    Atypical teratoid rhabdoid tumor (ATRT) is an aggressive tumor of the CNS and characteristically occurs in the pediatric age. In adulthood, ATRT is rare and it is mainly localized in the cerebral hemispheres. Only 16 cases of ATRT have been described in the sellar region up to now. Read More

    A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas.
    Oncotarget 2017 Oct 7;8(45):79111-79125. Epub 2017 Mar 7.
    Department of Neurosurgery, Fuzhou General Hospital, Fujian Medical University, Fuzhou, P. R. China.
    The purpose of this study was to investigate the differences between pre- and postoperative pituitary hormone levels in patients undergoing surgical resection of pituitary adenoma and to identify factors associated with preoperative hypopituitarism. Data from 81 patients with histologically confirmed functioning and non-functioning pituitary adenomas (NFPA) who underwent transsphenoidal resection from January 2011 to December 2013 were retrospectively analyzed. Logistic regression was applied to analyze factors associated with preoperative hypopituitarism. Read More

    Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.
    Int J Mol Sci 2017 Nov 1;18(11). Epub 2017 Nov 1.
    Laboratory of Neuroendocrinology, INCyL and IBSAL, University of Salamanca, 37007 Salamanca, Spain.
    The pituitary gland is part of hypothalamic-pituitary-gonadal axis, which controls development, reproduction, and aging in humans and animals. In addition, the pituitary gland is regulated mainly by hormones and neurotransmitters released from the hypothalamus and by systemic hormones secreted by target glands. Aromatase P450, the enzyme responsible for the catabolization of aromatizable androgens to estrogens, is expressed in different parts of body, including the pituitary gland. Read More

    Pituitary Adenoma Associated With Rathke's Cleft Cyst: Report of 15 Cases.
    Can J Neurol Sci 2017 Nov 6:1-8. Epub 2017 Nov 6.
    1Department of Neurosurgery, Beijing Tiantan Hospital,Capital Medical University,Beijing,China.
    Objective: The concomitant presence of pituitary adenoma (PA) with Rathke's cleft cyst (RCC) is rare, and most of the literature published is case reports. RCC's clinicopathological features have not been well described.

    Methods: We retrospectively reviewed the data of 15 patients with PA associated with RCC. Read More

    Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
    BMJ Case Rep 2017 Nov 3;2017. Epub 2017 Nov 3.
    Division of Neurosurgery, National University Hospital (NUH), Singapore.
    Presently, the standard of care for prolactinomas, a type of pituitary adenoma, is dopaminergic agents such as bromocriptine and cabergoline. However, dopaminergic agents may induce fibrosis of cardiac valves leading to valvular insufficiency, necessitating surgical treatment of prolactinoma. Fibrosis of prolactinoma can be induced by prolonged medical treatment with bromocriptine, and this usually occurs after years of treatment. Read More

    AIP mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation.
    Endocr Connect 2017 Oct 26. Epub 2017 Oct 26.
    M Gadelha, Internal Medicine and Endocrine Unit, Universidade Federal do Rio de Janeiro Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil.
    Aryl hydrocarbon receptor-interacting protein (AIP) gene mutations (AIPmut) are the most frequent germline mutations found in apparently sporadic pituitary adenomas (SPA). Our aim was to evaluate the frequency of AIPmut among young Brazilian patients with SPA. We performed an observational cohort study between 2013-2016 in a single referral center. Read More

    Sex differences in the pituitary TGFβ1 system: The role of TGFβ1 in prolactinoma development.
    Front Neuroendocrinol 2017 Oct 24. Epub 2017 Oct 24.
    Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, V. Obligado 2490, 1428 Buenos Aires, Argentina. Electronic address:
    Prolactinomas are the most frequent functioning pituitary adenomas, and sex differences in tumor size, behavior and incidence have been described. These differences have been associated with earlier diagnosis in woman, as well as with serum estradiol levels. Experimental models of prolactinomas in rodents also show a higher incidence in females, and recent findings suggest that gender differences in the transforming growth factor beta 1 (TGFβ1) system might be involved in the sex-specific development of prolactinomas in these models. Read More

    Novel Germline p.Gly42Val MEN1 Mutation in a Family with Multiple Endocrine Neoplasia Type 1 - Excellent Response of Prolactinoma to Cabergoline.
    Ann Clin Lab Sci 2017 Sep;47(5):606-610
    Endocrinology, William Harvey Research Institute, Bart's and the London School of Medicine, Queen Mary University of London, London, UK
    We report on a 27-year-old male patient presenting with renal colic secondary to hyperparathyroidism. Further investigations confirmed a diagnosis of type 1 multiple endocrine neoplasia and revealed a 2.0 cm pancreatic neuroendocrine tumour as well as a pituitary macroadenoma with significantly elevated prolactin levels. Read More

    Males with prolactinoma are at increased risk of incident cardiovascular disease.
    Clin Endocrinol (Oxf) 2017 Oct 16. Epub 2017 Oct 16.
    Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
    Objective: To investigate whether the risk of incident cardiovascular disease (CVD) is increased in patients with prolactinoma.

    Design: Population-based, retrospective, open-cohort study using The Health Improvement Network (THIN) database.

    Patients: A total of 2233 patients with prolactinoma and 10 355 matched controls (1:5 ratio) from UK General Practices contributing to THIN were included. Read More

    Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.
    Endocrine 2017 Oct 17. Epub 2017 Oct 17.
    Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
    Purpose: Dopamine agonists (DAs) are recommended as first-line treatment for patients with hyperprolactinemia. Generally, it is accepted that patients with hyperprolactinemia do not need lifelong medication, but the optimal timing for DA withdrawal has not been determined. The aim of this systematic review and meta-analysis is to assess the impact of DA withdrawal on the clinical outcomes of patients with hyperprolactinemia, and to explore possible factors affecting successful DA withdrawal. Read More

    Analysis of MEN1 c.482G>A (p.Gly161Asp) mutation in a pedigree with familial multiple endocrine neoplasia type 1.
    Mol Med Rep 2017 Dec 10;16(6):8973-8976. Epub 2017 Oct 10.
    Department of Endocrinology and Metabolism, Genetic and Prenatal Diagnosis Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
    Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the development of neuroendocrine tumors, which in turn are caused by mutations in the MEN1 gene. In the present study, a case of a 46‑year‑old woman who was clinically diagnosed with MEN1 based on the presence of prolactinoma and bilateral parathyroid adenoma was reported. The patient's serum prolactin (PRL) levels were successfully controlled via bromocriptine therapy, and the serum levels of calcium and intact parathyroid hormone (PTH) reduced one day following parathyroidectomy. Read More

    Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
    Int Clin Psychopharmacol 2017 Oct 13. Epub 2017 Oct 13.
    Departments of aMental Health, CIBERSAM bEndocrinology, Corporació Sanitària Parc Taulí, Sabadell, Spain.
    Hyperprolactinaemia may affect sexual and reproductive functioning. However, recent studies suggest that increased prolactin levels may also have negative effects on cognition. We aimed to study whether the reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive tasks. Read More

    α-Glucosidase inhibitory and cytotoxic botryorhodines from mangrove endophytic fungus Trichoderma sp. 307.
    Nat Prod Res 2017 Oct 12:1-6. Epub 2017 Oct 12.
    a School of Marine Sciences , Sun Yat-Sen University , Guangzhou , China.
    One new depsidone, botryorhodine H (1), together with three known analogues, botryorhodines C, D and G (2-4), were obtained from the mangrove endophytic fungus Trichoderma sp. 307 by co-culturing with Acinetobacter johnsonii B2. Structures were determined by 1D and 2D NMR analyses and high-resolution mass spectrum. Read More

    Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center.
    J Endocrinol Invest 2017 Oct 11. Epub 2017 Oct 11.
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 806, Vila Clementino, São Paulo, CEP 04023-062, Brazil.
    Purpose: TSH-secreting pituitary adenomas are among the less prevalent pituitary tumors, corresponding to 0.9-1.5% of all pituitary adenomas in surgical series. Read More

    SUBCLINICAL IMPAIRMENT OF THE LEFT VENTRICULAR LONGITUDINAL FUNCTION IN PATIENTS WITH PROLACTINOMAS.
    Endocr Pract 2017 Oct 11. Epub 2017 Oct 11.
    From: Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
    Purpose Hyperprolactinemia has been associated with endothelial dysfunction and a wide range of cardiovascular risk factors, thus it can potentially lead to cardiac dysfunction. The present study was designed to interrogate our hypothesis that hyperprolactinemia can contribute to preclinical impaired left ventricular function. Patients and Methods Thirty-one prolactinoma patients and sixty healthy volunteers were prospectively recruited. Read More

    Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
    J Clin Endocrinol Metab 2017 Oct;102(10):3692-3703
    Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
    Context: The dopamine agonist cabergoline (CAB) has been used widely in the treatment of prolactinomas and other types of pituitary adenomas, but its clinical use is hampered by intolerance in some patients with prolactinoma and lack of effectiveness in other pituitary tumor types. Chloroquine (CQ) is an old drug widely used to treat malaria. Recent studies, including our own, have revealed that CAB and CQ are involved in induction of autophagy and activation of autophagic cell death. Read More

    Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
    Horm Res Paediatr 2017 Sep 26. Epub 2017 Sep 26.
    Endocrinology Service, Brasília University Hospital, Brasília, Brazil.
    Introduction: Prolactinomas are pituitary tumors with a very low prevalence in childhood and adolescence compared to adulthood. This condition is preferentially treated with dopamine agonists. Resistance to these drugs is rare. Read More

    Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report.
    Gynecol Endocrinol 2017 Sep 19:1-3. Epub 2017 Sep 19.
    a Department of Obstetrics and Gynecology , Hyogo Prefectural Amagasaki General Medical Center , Amagasaki , Japan.
    Prolactin-producing uterine leiomyomas are very rare. Although hyperprolactinemia rapidly improves after removal of such leiomyomas, no preoperative diagnostic test has been established for prolactin-producing uterine leiomyomas. A 45-year-old Japanese woman, gravida 3 para 3, was referred to our hospital for further examination of hyperprolactinemia resistant to a dopamine agonist. Read More

    Notch system is differentially expressed and activated in pituitary adenomas of distinct histotype, tumor cell lines and normal pituitaries.
    Oncotarget 2017 Aug 6;8(34):57072-57088. Epub 2017 Jul 6.
    Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires, CITNOBA (UNNOBA-CONICET), Universidad Nacional del Noroeste de la Provincia de Buenos Aires, Pergamino, 2700 Buenos Aires, Argentina.
    Pituitary adenomas are among the most frequent intracranial neoplasms and treatment depends on tumor subtype and clinical features. Unfortunately, non responder cases occur, then new molecular targets are needed. Notch system component expression and activation data are scarce in pituitary tumorigenesis, we therefore aimed to characterize Notch system in pituitary tumors of different histotype. Read More

    [Prolactin-secreting microadenoma in menopausal women].
    Pan Afr Med J 2017 5;27:177. Epub 2017 Jul 5.
    Service d'Endocrinologie, CHU Farhat Hached de Sousse, Tunisie.
    Prolactin-secreting adenoma is rare in elderly women. Patient's clinical picture may be confused with that of menopause, making diagnosis sometimes difficult. We report the case of a 57-year old woman with a 2-year history of secondary amenorrhea without hot flushes associated with galactorrhea in order to highlight the peculiarities of prolactin-secreting microadenomas. Read More

    Cerebrospinal Fluid Leak Rhinorrhea after Systemic Erlotinib Chemotherapy for Metastatic Lung Cancer: A Familiar Problem from an Unfamiliar Culprit.
    World Neurosurg 2017 Sep 5. Epub 2017 Sep 5.
    Department of Neurological Surgery, Wexner Medical Center, The Ohio State University, College of Medicine, Columbus, Ohio; Department of Otolaryngology-Head and Neck Surgery, Wexner Medical Center, The Ohio State University, College of Medicine, Columbus, Ohio. Electronic address:
    Background: Cerebrospinal fluid (CSF) rhinorrhea after medical therapy for pituitary prolactinoma is a rare but well-described phenomenon. To our knowledge, no CSF leaks have been reported after targeted medical treatment of pituitary or anterior skull base metastases. We report this unusual case to raise awareness of spontaneous CSF leaks in the setting of skull base metastatic disease. Read More

    Lesson to be remembered from a skull base tumor.
    Neurochirurgie 2017 Sep 4;63(4):334-335. Epub 2017 Sep 4.
    Institut Mitovasc, unité CNRS 6214/Inserm1083, université d'Angers, 49100 Angers, France; Service d'endocrinologie diabétologie nutrition, centre de référence des maladies rares de la réceptivité hormonale, CHU d'Angers, Angers, France. Electronic address:
    The natural history of giant prolactinomas is not known. While it is commonly accepted that the enlargement of microadenoma is rare and more limited than macroadenoma, it is so far uncommon that macroadenoma progress to giant adenoma. Thus, spontaneous enlargement of adenomas is poorly documented. Read More

    Dopamine Agonists and Impulse Control Disorders: A Complex Association.
    Drug Saf 2017 Aug 31. Epub 2017 Aug 31.
    Clinical Investigation Unit "Behavioral Addictions/Complex Affective Disorders", Addictology and Psychiatry Department, CHU Nantes, Hospital Saint Jacques, 85, rue Saint Jacques, 44093, Nantes Cedex 1, France.
    Impulse control disorders (ICDs) are a well-known adverse effect of dopamine agonists (DAAs). This critical review aims to summarize data on the prevalence and factors associated with the development of an ICD simultaneous to DAA use. A search of two electronic databases was completed from inception to July 2017. Read More

    Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms.
    Pituitary 2017 Dec;20(6):676-682
    Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
    Purpose: Internal carotid artery (ICA) aneurysms have rarely been found in association with marked hyperprolactinemia in the absence of prolactinoma; the cause of hyperprolactinemia has never been investigated. We aimed to determine if the observed hyperprolactinemia is due to a vascular-derived or known prolactin secretagogue from the injured ICA, analogous to pregnancy-associated hyperprolactinemia putatively due to placental factors.

    Methods: We conducted a case series and literature review of individuals with severe hyperprolactinemia in association with ICA aneurysms. Read More

    Clinical characteristics of pituitary adenomas with radiological calcification.
    Acta Neurochir (Wien) 2017 Nov 19;159(11):2187-2192. Epub 2017 Aug 19.
    Department of Neurosurgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
    Background: Radiographic detection of calcification in pituitary adenoma is relatively rare, and the clinical characteristics of pituitary adenoma with calcification remain unclear. Herein, the clinical characteristics of pituitary adenoma with radiological calcification were investigated.

    Methods: A total of 160 patients who underwent surgical resection of pituitary adenomas between February 2004 and December 2016 were reviewed. Read More

    Brain and Optic Chiasm Herniation into Sella after Pituitary Tumor Apoplexy.
    Front Endocrinol (Lausanne) 2017 7;8:192. Epub 2017 Aug 7.
    Clínica de Endocrinología y Metabolismo, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
    Brain and optic chiasm herniation has been rarely reported following dopamine agonist treatment for large prolactinomas. We report a case of brain and optical chiasm herniation, secondary to an empty sella due to apoplexy of a prolactinoma, and we focus on the specific presentation of this case. A 32-year-old female presented to a neurologist complaining of headaches. Read More

    [A rare case of giant galactocele associated with prolactinoma].
    Pan Afr Med J 2017 8;27:97. Epub 2017 Jun 8.
    Service de Gynécologie Obstétrique II, CHU Hassan II, Fès, Maroc.
    Galactocele is a rare cystic formation, a benign breast lesion, occurring when breast duct is blocked and engorged. It generally affects postpartum women, either breastfeeding or not. Only a few cases have been reported in the literature and they were not related to lactation, as in the case of postmenopausal women or of men; moreover, their relationship to the overproduction of prolactin, a growth factor stimulating mammary epithelial cells, is not very well defined at this time. Read More

    Prolactinoma in a Dog.
    Vet Pathol 2017 Nov 16;54(6):972-976. Epub 2017 Aug 16.
    6 Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
    A 12-year-old male Yorkshire Terrier was presented because of decreased appetite. Physical examination revealed mammary gland swelling and galactorrhea. Contrast-enhanced computed tomographic scanning of the skull indicated an enlarged pituitary gland, compatible with a pituitary tumor. Read More

    The partner's perspective of the impact of pituitary disease: Looking beyond the patient.
    J Health Psychol 2017 Mar 1:1359105317695427. Epub 2017 Mar 1.
    1 Leiden University Medical Center, The Netherlands.
    People with pituitary disease report impairments in quality of life. The aim of this study was to elucidate the impact of the pituitary condition on the lives of partners. Four focus groups of partners of people with pituitary disease (Cushing's disease, non-functioning adenoma, acromegaly, prolactinoma) were conducted. Read More

    Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review.
    Cancers (Basel) 2017 Aug 8;9(8). Epub 2017 Aug 8.
    Laboratory of Molecular Target Therapy for Cancer, Graduate School for Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.
    Pituitary adenomas are often treated with radiotherapy for the management of tumor progression or recurrence. Despite the improvement in cure rates, patients treated by radiotherapy are at risk of development of secondary malignancies. We conducted a comprehensive literature review of the secondary intracranial tumors that occurred following radiotherapy to pituitary adenomas to obtain clinicopathological characteristics. Read More

    Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study.
    Endocrine 2017 Sep 19;57(3):486-493. Epub 2017 Jul 19.
    University Hospital of Endocrinology, Sofia, Bulgaria.
    Background: The potent immunomodulatory action of prolactin has been demonstrated in many experimental in vitro studies. In accordance with these data, our retrospective analyses revealed higher prevalence of autoimmune thyroid diseases in prolactinoma patients compared to general population.

    Purpose: A cross-sectional case-control study was carried out in a single tertiary referral centre. Read More

    A retrospective review of 34 cases of pediatric pituitary adenoma.
    Childs Nerv Syst 2017 Nov 18;33(11):1961-1967. Epub 2017 Jul 18.
    Department of Neurosurgery, West China Hospital, Sichuan University, 37th Guoxue Alley, Chengdu, China.
    Purpose: The purpose of this paper is to study invasiveness, tumor features and clinical symptoms of pediatric pituitary adenoma, and to discuss some inconclusive results in prior studies.

    Methods: We retrospectively reviewed 34 cases of children (<20 year-old) who were pathologically diagnosed with pituitary adenoma and surgically treated from 2010 to 2017. Data of general information, clinical symptoms, invasive behaviors, surgery approaches, and tumor features were collected and analyzed. Read More

    Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
    Pituitary 2017 Oct;20(5):578-584
    Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
    Purpose: Dopamine agonist (DA) therapy is recommended as the first-line treatment for prolactinomas. However, it requires long treatment duration, and a high recurrence rate after DA withdrawal has been reported. We aimed to elucidate the predictors for long-term remission following DA withdrawal and propose the best candidates who can achieve complete remission after DA withdrawal. Read More

    Pregnancy and Tumor Outcomes in Women with Prolactinoma.
    Exp Clin Endocrinol Diabetes 2017 Nov 13;125(10):642-648. Epub 2017 Jul 13.
    Faculty of Medicine, University of Porto. Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
    Context Management of prolactinomas during pregnancy has always been a challenge. There is a concern about the risk of tumor growth, as well as the effects of the treatment on the developing fetus. Another issue that has been less studied is the outcome of women with prolactinoma after pregnancy and lactation. Read More

    Recent Progress in the Medical Therapy of Pituitary Tumors.
    Endocrinol Metab (Seoul) 2017 Jun;32(2):162-170
    Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
    Management of pituitary tumors is multidisciplinary, with medical therapy playing an increasingly important role. With the exception of prolactin-secreting tumors, surgery is still considered the first-line treatment for the majority of pituitary adenomas. However, medical/pharmacological therapy plays an important role in controlling hormone-producing pituitary adenomas, especially for patients with acromegaly and Cushing disease (CD). Read More

    Menstrual Cycle Abnormalities in Patients with Prolactinoma and Drug-induced Hyperprolactinemia.
    Indian J Endocrinol Metab 2017 Jul-Aug;21(4):545-550
    Department of Endocrinology, PGIMER, Dr. RML Hospital, New Delhi, India.
    Background And Objective: Hyperprolactinemia affects the reproductive endocrine axis; however, the degree of dysfunction may vary depending on etiology. The aim of the present study was to analyze menstrual cyclicity in patients with prolactinoma and drug-induced hyperprolactinemia (DIH).

    Methodology: Patients with prolactinoma and DIH were retrospectively analyzed for menstrual cyclicity at presentation and response to therapy. Read More

    Radiological Growth Patterns of Prolactinomas and Nonfunctioning Adenomas.
    Can J Neurol Sci 2017 Sep 3;44(5):508-513. Epub 2017 Jul 3.
    1Division of Endocrinology and Metabolism,Dalhousie University,Halifax,Nova Scotia,Canada.
    Objectives: To compare growth patterns of nonfunctioning and prolactin-producing pituitary macroadenomas, and to find whether their specific growth patterns are associated with clinically significant effects on vision.

    Materials And Methods: From our comprehensive provincial neuropituitary registry, we retrospectively identified 35 randomly selected patients each with nonfunctioning adenomas and prolactinomas >10 mm in any dimension. MRI scans were analyzed to determine the superior and inferior growth, volume, and maximum craniocaudal height of the adenomas. Read More

    How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey.
    J Endocrinol Invest 2017 Jun 20. Epub 2017 Jun 20.
    Department of Endocrinology, Erciyes University Medical School, 38039, Kayseri, Turkey.
    Objective: Data regarding pregnancies in relation to pituitary tumors are limited. The effects of pregnancy on pituitary adenomas and the effects of adenoma itself (hormonal activity, mass effects and pituitary insufficiency) and/or treatment on the ongoing gestation and developing fetus were evaluated.

    Methods: The study was a retrospective study. Read More

    Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes.
    Clin Endocrinol (Oxf) 2017 Nov 18;87(5):508-514. Epub 2017 Jul 18.
    Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
    Objective: Most prolactinomas in females are diagnosed during the reproductive age, and the majority are microadenomas. Prolactinomas detected in the postmenopausal period are less common with limited published data on their presentation and prognosis. Our objective was to assess the presenting clinical, biochemical and imaging findings, as well as the outcomes of women diagnosed with a prolactinoma in the postmenopausal period. Read More

    Activation of DRD5 (dopamine receptor D5) inhibits tumor growth by autophagic cell death.
    Autophagy 2017 Aug 14;13(8):1404-1419. Epub 2017 Jun 14.
    a Department of Neurosurgery , First Affiliated Hospital of Wenzhou Medical University , Wenzhou , China.
    Dopamine agonists such as bromocriptine and cabergoline have been successfully used in the treatment of pituitary prolactinomas and other neuroendocrine tumors. However, their therapeutic mechanisms are not fully understood. In this study we demonstrated that DRD5 (dopamine receptor D5) agonists were potent inhibitors of pituitary tumor growth. Read More

    Course of Aggressive Somatotroph, Corticotroph and Mammotroph Tumors under Temozolomide; Report of Three Cases and Review of the Literature.
    Turk Neurosurg 2017 May 7. Epub 2017 May 7.
    Ankara University Faculty of Medicine, Department of Endocrinology and Metabolism.
    Treatment of aggressive pituitary tumors may be challenging. Temozolomide (TMZ) is a promising agent when conventional treatment methods fail. We present three patients with aggressive pituitary tumors with atypical morphology, who were resistant to conventional treatments and treated with TMZ. Read More

    25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma.
    Endocr Metab Immune Disord Drug Targets 2017 ;17(3):219-225
    Department of Microbiology at Specialized Medical Hospital, Mansoura University, Mansoura. Egypt.
    Objective: The present research explored the relationship of vitamin D status with prolactin levels and adenoma size in female patients with newly diagnosed prolactinoma and determination of hypovitaminosis D prevalence among female patients with prolactinoma.

    Patients And Methods: We enrolled 67 female patients with newly diagnosed prolactinoma (41 with micro adenoma and 26 with macro adenoma) in this case-control study at the time of presentation. We selected 45 female subjects as a control group who were matched according to age, weight, height, body mass index and waist circumference. Read More

    1 OF 67